Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucindolol in patients with chronic heart failure

Circulation: Arrhythmia and Electrophysiology

Volumn 6, Issue 1, 2013, Pages 137-143

  Aleong, Ryan G ^a   Sauer, William H ^a   Robertson, Alastair D ^b   Liggett, Stephen B ^c   Bristow, Michael R ^a,b  

^a UNIVERSITY OF COLORADO HOSPITAL   (United States)

^b ARCA Biopharma   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

blockers; Genetic polymorphisms; Pharmacogenetics; Ventricular arrhythmia

Indexed keywords

ADRENERGIC RECEPTOR; BUCINDOLOL; ADRA2C PROTEIN, HUMAN; ADRB1 PROTEIN, HUMAN; ALPHA 2 ADRENERGIC RECEPTOR; ANTIARRHYTHMIC AGENT; BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PROPANOLAMINE DERIVATIVE;

ADULT; ARTICLE; CARDIAC PATIENT; FEMALE; GENE DELETION; GENETIC VARIABILITY; GENOTYPE; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; WILD TYPE; CHI SQUARE DISTRIBUTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENETIC POLYMORPHISM; GENETICS; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HETEROZYGOTE; HOMOZYGOTE; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANTI-ARRHYTHMIA AGENTS; CHI-SQUARE DISTRIBUTION; FEMALE; HEART FAILURE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROPANOLAMINES; PROSPECTIVE STUDIES; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, ADRENERGIC, BETA-1; STROKE VOLUME; TACHYCARDIA, VENTRICULAR; TREATMENT OUTCOME; VENTRICULAR FIBRILLATION; VENTRICULAR FUNCTION, LEFT;

MLCS; MLOWN;

EID: 84876301296     PISSN: 19413149     EISSN: 19413084     Source Type: Journal    
DOI: 10.1161/CIRCEP.111.969618     Document Type: Article

References (27)

1. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13.
2. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001-2007.
3. Goldstein S, Fagerberg B, Hjalmarson A, Kjekshus J, Waagstein F, Wedel H, Wikstrand J; MERIT-HF Study Group. Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study. J Am Coll Cardiol. 2001;38:932-938.
4. Brodine WN, Tung RT, Lee JK, Hockstad ES, Moss AJ, Zareba W, Hall WJ, Andrews M, McNitt S, Daubert JP; MADIT-II Research Group. Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II). Am J Cardiol. 2005;96:691-695.
5. Metra M, Bristow MR. β-blocker therapy in chronic heart failure. In: Mann DL, ed. Heart Failure: A companion to Braunwald's Heart Disease. Philadelphia, PA: W.B Saunders; 2011:674-693.
6. Bucindolol Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659-1667.
7. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, Hodne D, Nelson B, Morrison J, Domanski MJ, Wagoner LE, Abraham WT, Anderson JL, Carlquist JF, Krause-Steinrauf HJ, Lazzeroni LC, Port JD, Lavori PW, Bristow MR. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci USA. 2006;103:11288-11293.
8. Bristow MR, Murphy GA, Krause-Steinrauf H, Anderson JL, Carlquist JF, Thaneemit-Chen S, Krishnan V, Abraham WT, Lowes BD, Port JD, Davis GW, Lazzeroni LC, Robertson AD, Lavori PW, Liggett SB. An alpha2Cadrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure. Circ Heart Fail. 2010;3:21-28.
9. 1, α2C adrenergic receptor polymorphisms. PLoS ONE. 2012;7:e44324.
10. Sandilands AJ, O'Shaughnessy KM, Brown MJ. Greater inotropic and cyclic AMP responses evoked by noradrenaline through Arg389 beta 1-adrenoceptors versus Gly389 beta 1-adrenoceptors in isolated human atrial myocardium. Br J Pharmacol. 2003;138:386-392.
11. Mialet Perez J, Rathz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, Schwartz A, Dorn GW, Liggett SB. Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med. 2003;9:1300-1305.
12. Hein L, Altman JD, Kobilka BK. Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission. Nature. 1999;402:181-184.
13. Brede M, Wiesmann F, Jahns R, Hadamek K, Arnolt C, Neubauer S, Lohse MJ, Hein L. Feedback inhibition of catecholamine release by two different alpha2-adrenoceptor subtypes prevents progression of heart failure. Circulation. 2002;106:2491-2496.
14. Small KM, Forbes SL, Rahman FF, Bridges KM, Liggett SB. A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors. J Biol Chem. 2000;275:23059-23064.
15. The BEST Steering Committee. Design of the Beta-Blocker Evaluation Survival Trial (BEST). Am J Cardiol. 1995;75:1220-1223.
16. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94: 496-509.
17. Pintilie M. Competing Risks: A Practical Perspective. Chichester, England: John Wiley & Sons, Inc; 2006.
18. Cantor A. Extending SAS Survival Analysis Techniques for Medical Research. Cary, NC: SAS Institute Inc; 1997.
19. Woodcock J, Lesko LJ. Pharmacogenetics-tailoring treatment for the outliers. N Engl J Med. 2009;360:811-813.
20. Schmoor C, Sauerbrei W, Schumacher M. Sample size considerations for the evaluation of prognostic factors in survival analysis. Stat Med. 2000;19:441-452.
21. Mason DA, Moore JD, Green SA, Liggett SB. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem. 1999;274:12670-12674.
22. Dockstader K, Nunley K, Karimpour-Fard A, Medway A, Nelson P, Port JD, Liggett SB, Bristow MR, Sucharov CC. Temporal analysis of mRNA and miRNA expression in transgenic mice overexpressing Argand Gly389 polymorphic variants of the β1-adrenergic receptor. Physiol Genomics. 2011;43:1294-1306.
23. White HL, de Boer RA, Maqbool A, Greenwood D, van Veldhuisen DJ, Cuthbert R, Ball SG, Hall AS, Balmforth AJ; MERIT-HF Study Group. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur J Heart Fail. 2003;5:463-468.
24. Sehnert AJ, Daniels SE, Elashoff M, Wingrove JA, Burrow CR, Horne B, Muhlestein JB, Donahue M, Liggett SB, Anderson JL, Kraus WE. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. J Am Coll Cardiol. 2008;52:644-651.
25. Bristow MR, Krause-Steinrauf H, Nuzzo R, Liang CS, Lindenfeld J, Lowes BD, Hattler B, Abraham WT, Olson L, Krueger S, Thaneemit-Chen S, Hare JM, Loeb HS, Domanski MJ, Eichhorn EJ, Zelis R, Lavori P. Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial. Circulation. 2004;110:1437-1442.
26. Luu M, Stevenson WG, Stevenson LW, Baron K, Walden J. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation. 1989;80:1675-1680.
27. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, Wright TJ; MOXCON Investigators. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail. 2003;5:659-667.